4//SEC Filing
Elliott Russell P. 4
Accession 0001178913-18-000265
CIK 0001606645other
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 8:26 PM ET
Size
10.0 KB
Accession
0001178913-18-000265
Insider Transaction Report
Form 4
Elliott Russell P.
VP Drug Development
Transactions
- Exercise/Conversion
Ordinary Shares
2018-01-01+1,372→ 5,490 total - Exercise/Conversion
Restricted Share Units
2018-01-01−1,372→ 0 totalExercise: $0.00→ Ordinary Shares (1,372 underlying) - Tax Payment
Ordinary Shares
2018-01-02$5.98/sh−555$3,319→ 4,935 total
Footnotes (5)
- [F1]This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- [F2]The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 1,372 ordinary shares underlying restricted share units that vested on January 1, 2018 and (ii) 4,118 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
- [F3]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of restricted share units.
- [F4]The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021.
- [F5]This class of restricted share units is included in Column 5 of Table I above.
Documents
Issuer
Foamix Pharmaceuticals Ltd.
CIK 0001606645
Entity typeother
Related Parties
1- filerCIK 0001727807
Filing Metadata
- Form type
- 4
- Filed
- Jan 23, 7:00 PM ET
- Accepted
- Jan 24, 8:26 PM ET
- Size
- 10.0 KB